All In Biotech

Drug Trial Radar · NCT07140484

Sotatercept in Pulmonary Arterial Hypertension

A Single-arm, Open-label Phase IV Study to Evaluate the Effectiveness of Sotatercept in Improving Pulmonary Vascular Recruitment in Patients With Pulmonary Arterial Hypertension (PAH)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Oct 6, 2025

Primary completion

Jan 1, 2029

Study completion Jan 1, 2030

Sponsor

Lead sponsor
University of AlbertaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Canada Inc.; Alberta Health services
First posted
Aug 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine whether sotatercept is effective in improving diffusing capacity in patients with pulmonary arterial hypertension. Participants will be asked to: * Take Sotatercept every 21 days (±3 days) * Each participant will be enrolled in the study for 29 Weeks * Visit the clinic 18 times * Have a physical exam * Perform assessments of lung function and exercise tests * Have an ultrasound of their heart * Have blood draws done at regular intervals The main objectives of the study are: Primary objective: To assess whether sotatercept will improve recruitment of diffusing membrane capacity (DM) with exercise. Secondary objective: To identify components of the diffusing capacity that respond to treatment with sotatercept in pulmonary arterial hypertension.

Conditions

  • Pulmonary Artery Hypertension

Interventions

  • SotaterceptDrug

    0.7mg/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Lung diffusing capacityTime frame: 6 weeks post starting treatment
  2. Lung diffusing capacityTime frame: 23 weeks post starting treatment
  3. Diffusing membrane capacity (Dm)Time frame: 6 weeks post starting treatment
  4. Diffusing membrane capacity (Dm)Time frame: 23 weeks post starting treatment
  5. Pulmonary capillary blood volume (Vc)Time frame: 6 weeks post starting treatment
  6. Pulmonary capillary blood volume (Vc)Time frame: 23 weeks post starting treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Physiology Laboratory

    Edmonton, Alberta, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.